vs

Side-by-side financial comparison of Brown–Forman (BF.B) and DENTSPLY SIRONA Inc. (XRAY). Click either name above to swap in a different company.

Brown–Forman is the larger business by last-quarter revenue ($1.0B vs $961.0M, roughly 1.1× DENTSPLY SIRONA Inc.). Brown–Forman runs the higher net margin — 21.6% vs -15.2%, a 36.8% gap on every dollar of revenue. On growth, DENTSPLY SIRONA Inc. posted the faster year-over-year revenue change (6.2% vs -5.4%). Brown–Forman produced more free cash flow last quarter ($107.0M vs $60.0M). Over the past eight quarters, DENTSPLY SIRONA Inc.'s revenue compounded faster (0.4% CAGR vs -1.6%).

Brown-Forman Corporation is an American family-controlled publicly traded company, one of the largest in the spirits and wine business. Based in Louisville, Kentucky, it manufactures several very well known brands throughout the world, including Jack Daniel's, Old Forester, Woodford Reserve, GlenDronach, BenRiach, Glenglassaugh, Herradura, Korbel, and Chambord. Brown-Forman formerly owned Southern Comfort and Tuaca before selling them off in 2016.

Dentsply Sirona Inc. is an American dental equipment manufacturer and dental consumables producer that markets its products in over 120 countries. It has factories in 21 countries. The present company is largely the result of a merger in 1993 in which Gendex Corporation acquired Dentsply International Inc. for $590 million.

BF.B vs XRAY — Head-to-Head

Bigger by revenue
BF.B
BF.B
1.1× larger
BF.B
$1.0B
$961.0M
XRAY
Growing faster (revenue YoY)
XRAY
XRAY
+11.6% gap
XRAY
6.2%
-5.4%
BF.B
Higher net margin
BF.B
BF.B
36.8% more per $
BF.B
21.6%
-15.2%
XRAY
More free cash flow
BF.B
BF.B
$47.0M more FCF
BF.B
$107.0M
$60.0M
XRAY
Faster 2-yr revenue CAGR
XRAY
XRAY
Annualised
XRAY
0.4%
-1.6%
BF.B

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
BF.B
BF.B
XRAY
XRAY
Revenue
$1.0B
$961.0M
Net Profit
$224.0M
$-146.0M
Gross Margin
59.4%
46.1%
Operating Margin
29.4%
-14.5%
Net Margin
21.6%
-15.2%
Revenue YoY
-5.4%
6.2%
Net Profit YoY
-13.2%
66.0%
EPS (diluted)
$0.47
$-0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BF.B
BF.B
XRAY
XRAY
Q4 25
$1.0B
$961.0M
Q3 25
$924.0M
$904.0M
Q2 25
$894.0M
$936.0M
Q1 25
$1.0B
$879.0M
Q4 24
$1.1B
$905.0M
Q3 24
$951.0M
$951.0M
Q2 24
$964.0M
$984.0M
Q1 24
$1.1B
$953.0M
Net Profit
BF.B
BF.B
XRAY
XRAY
Q4 25
$224.0M
$-146.0M
Q3 25
$170.0M
$-427.0M
Q2 25
$146.0M
$-45.0M
Q1 25
$270.0M
$20.0M
Q4 24
$258.0M
$-430.0M
Q3 24
$195.0M
$-494.0M
Q2 24
$266.0M
$-4.0M
Q1 24
$285.0M
$18.0M
Gross Margin
BF.B
BF.B
XRAY
XRAY
Q4 25
59.4%
46.1%
Q3 25
59.7%
48.8%
Q2 25
57.4%
52.4%
Q1 25
59.8%
53.0%
Q4 24
59.0%
49.3%
Q3 24
59.4%
52.1%
Q2 24
59.0%
51.9%
Q1 24
59.4%
53.1%
Operating Margin
BF.B
BF.B
XRAY
XRAY
Q4 25
29.4%
-14.5%
Q3 25
28.1%
-24.1%
Q2 25
22.9%
-13.7%
Q1 25
27.1%
7.2%
Q4 24
31.1%
-56.2%
Q3 24
29.5%
-48.6%
Q2 24
38.9%
5.1%
Q1 24
34.9%
4.4%
Net Margin
BF.B
BF.B
XRAY
XRAY
Q4 25
21.6%
-15.2%
Q3 25
18.4%
-47.2%
Q2 25
16.3%
-4.8%
Q1 25
26.1%
2.3%
Q4 24
23.6%
-47.5%
Q3 24
20.5%
-51.9%
Q2 24
27.6%
-0.4%
Q1 24
26.7%
1.9%
EPS (diluted)
BF.B
BF.B
XRAY
XRAY
Q4 25
$0.47
$-0.74
Q3 25
$0.36
$-2.14
Q2 25
$0.31
$-0.22
Q1 25
$0.57
$0.10
Q4 24
$0.55
$-2.09
Q3 24
$0.41
$-2.46
Q2 24
$0.56
$-0.02
Q1 24
$0.60
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BF.B
BF.B
XRAY
XRAY
Cash + ST InvestmentsLiquidity on hand
$319.0M
$326.0M
Total DebtLower is stronger
$2.4B
$2.3B
Stockholders' EquityBook value
$4.1B
$1.3B
Total Assets
$8.2B
$5.4B
Debt / EquityLower = less leverage
0.59×
1.70×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BF.B
BF.B
XRAY
XRAY
Q4 25
$319.0M
$326.0M
Q3 25
$471.0M
$363.0M
Q2 25
$444.0M
$359.0M
Q1 25
$599.0M
$398.0M
Q4 24
$416.0M
$272.0M
Q3 24
$416.0M
$296.0M
Q2 24
$446.0M
$279.0M
Q1 24
$589.0M
$291.0M
Total Debt
BF.B
BF.B
XRAY
XRAY
Q4 25
$2.4B
$2.3B
Q3 25
$2.4B
Q2 25
$2.4B
Q1 25
$2.7B
Q4 24
$2.7B
$1.7B
Q3 24
$2.7B
Q2 24
$2.7B
Q1 24
$2.7B
Stockholders' Equity
BF.B
BF.B
XRAY
XRAY
Q4 25
$4.1B
$1.3B
Q3 25
$4.0B
$1.5B
Q2 25
$4.0B
$2.0B
Q1 25
$3.8B
$2.0B
Q4 24
$3.7B
$1.9B
Q3 24
$3.5B
$2.5B
Q2 24
$3.5B
$3.1B
Q1 24
$3.2B
$3.3B
Total Assets
BF.B
BF.B
XRAY
XRAY
Q4 25
$8.2B
$5.4B
Q3 25
$8.2B
$5.7B
Q2 25
$8.1B
$6.1B
Q1 25
$8.1B
$6.0B
Q4 24
$8.3B
$5.8B
Q3 24
$8.2B
$6.6B
Q2 24
$8.2B
$6.9B
Q1 24
$8.2B
$7.1B
Debt / Equity
BF.B
BF.B
XRAY
XRAY
Q4 25
0.59×
1.70×
Q3 25
0.61×
Q2 25
0.61×
Q1 25
0.70×
Q4 24
0.73×
0.90×
Q3 24
0.77×
Q2 24
0.76×
Q1 24
0.83×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BF.B
BF.B
XRAY
XRAY
Operating Cash FlowLast quarter
$132.0M
$101.0M
Free Cash FlowOCF − Capex
$107.0M
$60.0M
FCF MarginFCF / Revenue
10.3%
6.2%
Capex IntensityCapex / Revenue
2.4%
4.3%
Cash ConversionOCF / Net Profit
0.59×
TTM Free Cash FlowTrailing 4 quarters
$610.0M
$104.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BF.B
BF.B
XRAY
XRAY
Q4 25
$132.0M
$101.0M
Q3 25
$160.0M
$79.0M
Q2 25
$152.0M
$48.0M
Q1 25
$317.0M
$7.0M
Q4 24
$112.0M
$87.0M
Q3 24
$17.0M
$141.0M
Q2 24
$285.0M
$208.0M
Q1 24
$265.0M
$25.0M
Free Cash Flow
BF.B
BF.B
XRAY
XRAY
Q4 25
$107.0M
$60.0M
Q3 25
$129.0M
$40.0M
Q2 25
$102.0M
$16.0M
Q1 25
$272.0M
$-12.0M
Q4 24
$81.0M
$36.0M
Q3 24
$-24.0M
$98.0M
Q2 24
$205.0M
$156.0M
Q1 24
$196.0M
$-9.0M
FCF Margin
BF.B
BF.B
XRAY
XRAY
Q4 25
10.3%
6.2%
Q3 25
14.0%
4.4%
Q2 25
11.4%
1.7%
Q1 25
26.3%
-1.4%
Q4 24
7.4%
4.0%
Q3 24
-2.5%
10.3%
Q2 24
21.3%
15.9%
Q1 24
18.3%
-0.9%
Capex Intensity
BF.B
BF.B
XRAY
XRAY
Q4 25
2.4%
4.3%
Q3 25
3.4%
4.3%
Q2 25
5.6%
3.4%
Q1 25
4.3%
2.2%
Q4 24
2.8%
5.6%
Q3 24
4.3%
4.5%
Q2 24
8.3%
5.3%
Q1 24
6.5%
3.6%
Cash Conversion
BF.B
BF.B
XRAY
XRAY
Q4 25
0.59×
Q3 25
0.94×
Q2 25
1.04×
Q1 25
1.17×
0.35×
Q4 24
0.43×
Q3 24
0.09×
Q2 24
1.07×
Q1 24
0.93×
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BF.B
BF.B

Whiskey$771.0M74%
Ready To Drink$138.0M13%
Tequila$67.0M6%
Restofportfolio$52.0M5%
Nonbrandedandbulk$8.0M1%

XRAY
XRAY

Essential Dental Solutions$372.0M39%
Equipment And Instruments$160.0M17%
Implants And Prosthetics$150.0M16%
CADCAM$139.0M14%
Wellspect Healthcare$88.0M9%
Orthodontics$52.0M5%

Related Comparisons